# Phase II Trial of ART + Dual bNAbs vs. ART + Placebo During Primary HIV-1 Infection-impact on Post-ART Control

> **NCT05300035** · PHASE2 · RECRUITING · sponsor: **ANRS, Emerging Infectious Diseases** · enrollment: 69 (estimated)

## Conditions studied

- HIV/AIDS and Infections

## Interventions

- **DRUG:** Recombinant human monoclonal antibody (bNAbs)
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05300035
- **Lead sponsor:** ANRS, Emerging Infectious Diseases
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-04-11
- **Primary completion:** 2026-12-10
- **Final completion:** 2028-12-10
- **Target enrollment:** 69 (ESTIMATED)
- **Last updated:** 2024-12-27

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05300035

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05300035, "Phase II Trial of ART + Dual bNAbs vs. ART + Placebo During Primary HIV-1 Infection-impact on Post-ART Control". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT05300035. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*